整合酶抑制剂遗传屏障排序： RAL > EVG > CAB > DTG 和 BIC
即拉替拉韦小于艾维雷韦小于卡博替韦小于多替拉韦和比克替拉韦
来源：Oliveira M, Ibanescu RI, Anstett K, Mésplède T, Routy JP, Robbins MA, Brenner BG; Montreal Primary HIV (PHI) Cohort Study Group. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018 Aug 17;15(1):56. doi: 10.1186/s12977-018-0440-3. PMID: 30119633; PMCID: PMC6098636.
即拉替拉韦小于艾维雷韦小于卡博替韦小于多替拉韦和比克替拉韦
来源：Oliveira M, Ibanescu RI, Anstett K, Mésplède T, Routy JP, Robbins MA, Brenner BG; Montreal Primary HIV (PHI) Cohort Study Group. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018 Aug 17;15(1):56. doi: 10.1186/s12977-018-0440-3. PMID: 30119633; PMCID: PMC6098636.
